ID   Kasumi-9
AC   CVCL_8488
SY   KASUMI-9; Kasumi9
DR   GEO; GSM4254137
DR   GEO; GSM5137721
DR   GEO; GSM5137759
DR   JCRB; JCRB1409
DR   PRIDE; PXD023662
DR   Wikidata; Q54899526
RX   PubMed=32180206;
RX   PubMed=32504922;
RX   PubMed=35124168;
RX   PubMed=35354797;
CC   Population: Japanese.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=32180206).
CC   Sequence variation: Gene fusion; HGNC; 6997; MEF2D + HGNC; 17011; HNRNPUL1; Name(s)=MEF2D-HNRNPUL1 (PubMed=32504922; PubMed=35354797).
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: STR profile from personal communication of Leo I.R.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): JCRB; Direct_author_submission
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D10S1248: 12,14
ST   D12S391: 19,24
ST   D13S317: 8,9
ST   D16S539: 11,13
ST   D18S51: 13,15
ST   D19S433: 13,14.2
ST   D1S1656: 16,18.3
ST   D21S11: 30
ST   D22S1045: 15,16
ST   D2S1338: 17,19
ST   D2S441: 10,14
ST   D3S1358: 16,17
ST   D5S818: 12
ST   D7S820: 8,10
ST   D8S1179: 14,17
ST   DYS391: 10
ST   FGA: 22,23
ST   SE33: 26.2,30.2
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C9143; Adult B acute lymphoblastic leukemia
DI   ORDO; Orphanet_99860; Precursor B-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 16
//
RX   PubMed=32180206; DOI=10.1007/s13577-020-00347-5;
RA   Kasai F., Asou H., Ozawa M., Kobayashi K., Kuramitsu H., Satoh M.,
RA   Kohara A., Kaneko Y., Kawamura M.;
RT   "Kasumi leukemia cell lines: characterization of tumor genomes with
RT   ethnic origin and scales of genomic alterations.";
RL   Hum. Cell 33:868-876(2020).
//
RX   PubMed=32504922; DOI=10.1016/j.biopha.2020.110330;
RA   Tange N., Hayakawa F., Yasuda T., Odaira K., Yamamoto H., Hirano D.,
RA   Sakai T., Terakura S., Tsuzuki S., Kiyoi H.;
RT   "Staurosporine and venetoclax induce the caspase-dependent proteolysis
RT   of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL
RT   cells.";
RL   Biomed. Pharmacother. 128:110330-110330(2020).
//
RX   PubMed=35124168; DOI=10.1016/j.jsbmb.2022.106068;
RA   Tamai M., Kasai S., Akahane K., Thu T.N., Kagami K., Komatsu C.,
RA   Abe M., Watanabe A., Goi K., Miyake K., Inaba T., Takita J., Goto H.,
RA   Minegishi M., Iwamoto S., Sugita K., Inukai T.;
RT   "Glucocorticoid receptor gene mutations confer glucocorticoid
RT   resistance in B-cell precursor acute lymphoblastic leukemia.";
RL   J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//